AIGENE was founded in 2020 to provide solutions to meet the "Unmet Needs" in the molecular diagnostics market, which is becoming more important due to the COVID-19 pandemic, based on various project experiences over the past 10 years, and is a bio-venture company that develops equipment and reagents for molecular diagnostics.

Using our molecular diagnostics platform technology, which offers scalability and differentiation, we are making progress in the rapidly growing respiratory virus diagnostics market, as well as the food safety and raw materials testing market, animal disease and origin diagnostics market, and more.

Meanwhile, we developed direct PCR reagents and extraction reagents that dramatically simplify the complex nucleic acid extraction process and automate all processes to complete accurate diagnosis within 1 hour, and developed innovative molecular diagnosis platform technology and launched nucleic acid extraction equipment (AIprep™ Purest96) and PCR equipment (AIamp™ Arcus96).

We are also promoting the Solution Provider business, which helps develop new and creative diagnostic platforms by converging and leveraging biotechnology (BT), information and communication technology (ICT), and nanotechnology (NT), with various partner companies. In addition, through strategic alliances with Chinese partners, we have built a lineup for each stage of Sample to Result.

Driven by our core values of efficiency, personalized approach, and data-driven, we are constantly innovating and constantly challenging ourselves to improve the accuracy of diagnostics by leveraging innovative technologies and data analytics for personalized treatment and prevention.

Under the banner of "Diagnostics to Solution, it's our Role," our members will make every effort to lead the global market with differentiated technologies and excellent business capabilities and to contribute to the healthy and happy lives of mankind by solidifying our position as a leading company in the field of molecular diagnostics.